CompaniesEngage Therapeutics

Engage Therapeutics

defunct

About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (2)

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

192

By Phase

PHASE1: 1PHASE2: 1

By Status

COMPLETED: 2

Clinical Trials Pipeline2 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2017

2018

2019

2020

2021

Today

Hover over trial bars to see details

Recent Trials

NCT03516305Lead Sponsor

Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers

PHASE1Completed

36 participants

Started: Apr 6, 2018 · Completed: Aug 1, 2018

NCT03478982Lead Sponsor

Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern

PHASE2Completed

156 participants

Started: Mar 16, 2018 · Completed: Jan 4, 2020

Funding History (2)

D

Oct 29, 2019

D

Oct 10, 2017

Related Companies

Ucb

acquired